Compare GSK plc (GSK) vs Micron Technology, Inc. (MU) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Micron Technology (MU) is trading at $848.81, down 13.66% amid a sector-wide selloff driven by fears of intensified Chinese competition and AI infrastructure bubble concerns. The stock shows strong fundamentals with Q1 2026 EPS beating expectations at $25.11 versus $20.98, and robust profitability metrics including a 55.91% net income margin. Technical indicators are bearish with key support at $781, while cash flow trends improved with 2025 net cash flow of $2.59 billion.

Outlook remains mixed: analyst consensus is strongly bullish with a $1,550 price target (81.43% buy ratings), but near-term risks include competitive pressures and volatility. Long-term growth is supported by AI-driven memory demand, though investors face headwinds from market sentiment shifts and geopolitical factors affecting semiconductor supply chains.